Developing new drugs to manage pain and substance use disorders
Official title: SPIGELMAN (UCLA) - MCSP- EXPLORATORY CHEMISTRY (EC)
Funded at Albany Molecular Research, INC. · NIH-11189220 · Data updated 2026-11-12
This study is working on new medications to help people manage pain better and tackle issues with substance use, aiming to create treatments that could improve your quality of life.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albany Molecular Research, INC. NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project start | August 18, 2023 |
| Project end | March 4, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,319,807 |
| NIH project number | 271201800001I-P00001-759502300003-1 |
| Project ID | NIH-11189220 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from chronic pain conditions or substance use disorders.
✕Less likely to help
Patients who do not have chronic pain or substance use issues may not benefit from this research.
What this research studies
This research focuses on creating new medications aimed at improving pain management and addressing substance use disorders. It utilizes advanced medicinal chemistry techniques, including the design and synthesis of small molecules that can selectively inhibit specific enzymes related to these conditions. The project involves a thorough evaluation of these compounds through various assays to determine their effectiveness and safety. Patients may benefit from innovative treatments that could enhance their quality of life and pain management options.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for managing pain and reducing substance use disorders.
How similar studies have gone: Previous research in medicinal chemistry has shown promise in developing effective treatments for pain and addiction, indicating a potential for success in this approach.
Where this research is happening
-
Albany Molecular Research, INC.
Albany, United States Active
Researchers
- Principal investigator: Surman, Matthew — Albany Molecular Research, INC.
- Study coordinator: Surman, Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.